Generic VEL/SOF With or Without RBV for HIV/HCV Coinfected Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

228

Participants

Timeline

Start Date

August 1, 2016

Primary Completion Date

July 15, 2017

Study Completion Date

October 31, 2017

Conditions
Hepatitis C Virus Infection, Response to Therapy ofHuman Immunodeficiency Virus
Interventions
DRUG

Sofosbuvir and Velpatasvir

All patients received a generic version of VEL/SOF fixed-dose combination (Sofosvel®, VEL/SOF 100/400 mg film coated tablet, Beacon Pharmaceuticals Ltd. Mymensingh, Bangladesh) 1 tablet per day for 12 weeks.

DRUG

Ribavirin

Patients with decompensated cirrhosis (Child-Pugh B or C), received weight-based ribavirin (RBV)(Robatrol®, 200 mg capsule, Genovate Biotechnology Co. Ltd., Hsinchu, Taiwan; 1,200 mg per day if the body weight ≥ 75 kg; 1,000 mg per day if the body weight \< 75 mg) for 12 weeks.

Trial Locations (2)

Unknown

National Taiwan University Hospital, Yun-Lin Branch, Douliu

National Taiwan University Hospital, Taipei

All Listed Sponsors
lead

National Taiwan University Hospital

OTHER

NCT03250910 - Generic VEL/SOF With or Without RBV for HIV/HCV Coinfected Patients | Biotech Hunter | Biotech Hunter